Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Staccato Loxapine (ADASUVE®) for Inhalation in Acutely Agitated Patients With Schizophrenia or Bipolar Disorder
NCT04148963 is registered in ClinicalTrials.gov with Lee's Pharmaceutical Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Staccato Loxapine (ADASUVE®) for Inhalation in Acutely Agitated Patients With Schizophrenia or Bipolar Disorder
- Lead sponsor
- Lee's Pharmaceutical Limited
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- December 1, 2019
- Completion date
- August 1, 2020
- Enrollment
- 150 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.